|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Bio-Path Holdings Inc is a US-based clinical and preclinical stage company. It focuses on oncology antisense drug development utilizing a novel technology. The company's drug delivery and antisense technology referred as DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by enzymes when circulating in vivo, incorporated inside of a neutrally charged lipid bilayer. The lead drug candidate of the company is prexigebersen which is a nonproprietary drug for acute myeloid leukemia as well as solid tumors, including breast cancer and ovarian cancer. Its other drug candidate is Liposomal Bcl2 which targets the protein Bcl2, which is responsible for driving cell proliferation of all cancers.
BPTH $21.98 +3.50 (18.94%)
Sector Health Care
Industry Drug Manufacturers
Market Cap 40 Million
EPS -2.58 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Wed, Mar 20, 2019
Dividend Pay Date --
Dividend History --
This list of trending stocks may change throughout the trading day.
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.